Publication | Closed Access

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

Breast OncologyPhase IiMedicinePharmacologyAnticancer ApproachBreast CancerAnti-cancer AgentCancer TreatmentOncologyCell BiologyEndocrine-related Cancer